Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Assessment of the Cardiovascular System I: Subjective Data01:23

Assessment of the Cardiovascular System I: Subjective Data

282
A thorough health history and physical assessment are essential for identifying cardiovascular disease (CVD) symptoms and distinguishing them from other health issues.
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
282
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

396
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
396

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical Patterns and Appropriateness of Apixaban Dosing in Patients With Atrial Fibrillation.

JACC. Advances·2026
Same author

Predictors of ischemic stroke and major bleeding among patients with atrial fibrillation in clinical practice.

American heart journal·2026
Same author

Integrative Clinical-Molecular Modeling Identifies <i>LRRN4CL</i> as a Determinant of Structural and Functional Myocardial Improvement.

bioRxiv : the preprint server for biology·2026
Same author

Self-supervised contrastive learning enables robust electrocardiogram-based cardiac classification.

Heart rhythm O2·2026
Same author

Determining the individualized probability of myocardial recovery: The multicenter RecoverHeart calculator.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2026
Same author

Hemodynamic Consequences and Clinical Outcomes With Intravenous Lidocaine Infusion in Patients With Atrial Fibrillation.

Journal of cardiovascular electrophysiology·2026
Same journal

Guideline-Directed Medical Therapy Use and Dose Optimization after TAVR in Patients with Persistent HFrEF.

Journal of cardiac failure·2026
Same journal

Heart Failure Pharmacotherapy Across the TAVR Continuum.

Journal of cardiac failure·2026
Same journal

Time to benefit of incretin-based therapies in adiposity-related heart failure with mildly reduced or preserved ejection fraction: a systematic review and meta-analysis.

Journal of cardiac failure·2026
Same journal

Predictors and Outcomes of Heart Failure Diagnosis in the Community When Compared to Acute Care Settings: Insights from Linked Administrative Health Databases.

Journal of cardiac failure·2026
Same journal

Digitalis Today: From Doctrine to Disrepute to Disciplined Reconsideration.

Journal of cardiac failure·2026
Same journal

What Are HFpEF Mimics and What Are They Mimicking? Insights Into Our Conceptualization of Heart Failure With Preserved Ejection Fraction as a Disease.

Journal of cardiac failure·2026
See all related articles

Related Experiment Video

Updated: Jun 12, 2025

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
03:47

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

728

Integration of Patient Reported Quality-of-life Data into Risk Assessment in Heart Failure.

Konstantinos Sideris1, Mingyuan Zhang2, Peter Wohlfahrt3

  • 1Division of Cardiovascular Medicine, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah.

Journal of Cardiac Failure
|September 19, 2024
PubMed
Summary
This summary is machine-generated.

Patient-reported outcomes (PROs) significantly enhance risk prediction for heart failure (HF) hospitalization and death in both HF with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF) patients. Integrating PROs into routine care improves clinical decision-making for HF management.

Keywords:
Patient-reported outcomesgradient boosting machine modelheart failure with preserved ejection fractionheart failure with reduced ejection fractionoutcomesquality of life

More Related Videos

Author Spotlight: Unveiling Prognostic Indicators in Heart Failure - The Role of Phase Angle and Bioelectrical Impedance Analysis
04:05

Author Spotlight: Unveiling Prognostic Indicators in Heart Failure - The Role of Phase Angle and Bioelectrical Impedance Analysis

Published on: June 30, 2023

1.7K
Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

7.6K

Related Experiment Videos

Last Updated: Jun 12, 2025

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
03:47

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

728
Author Spotlight: Unveiling Prognostic Indicators in Heart Failure - The Role of Phase Angle and Bioelectrical Impedance Analysis
04:05

Author Spotlight: Unveiling Prognostic Indicators in Heart Failure - The Role of Phase Angle and Bioelectrical Impedance Analysis

Published on: June 30, 2023

1.7K
Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

7.6K

Area of Science:

  • Cardiology
  • Health Informatics
  • Clinical Prediction Modeling

Background:

  • Optimal management of heart failure (HF) necessitates accurate, serial risk assessment for adverse outcomes.
  • Patient-reported outcomes (PROs) are increasingly integrated into clinical practice.
  • The utility of PROs in refining risk prediction models for ambulatory HF patients remains an area of investigation.

Purpose of the Study:

  • To evaluate whether incorporating PROs into risk prediction models improves accuracy for ambulatory patients with HF.
  • To assess the impact of PROs on predicting HF hospitalization and mortality.

Main Methods:

  • Utilized Cox regression with LASSO regularization and gradient boosting machine analyses.
  • Included consecutive patients with HF with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF) from a HF clinic (2015-2019).
  • Evaluated model performance using the time-dependent concordance index (Cτ).

Main Results:

  • Gradient boosting models incorporating PROs demonstrated superior prediction performance (Cτ = 0.73 for HFrEF, 0.74 for HFpEF).
  • Models showed excellent risk stratification across patient quintiles.
  • Key PROs influencing prediction included the Kansas City Cardiomyopathy Questionnaire, visual analogue scale, and Patient Reported Outcomes Measurement Information System dimensions.

Conclusions:

  • PROs significantly enhance risk prediction for both HFrEF and HFpEF patients, independent of traditional clinical factors.
  • Routine assessment of PROs, alongside electronic health record data, can lead to more accurate risk stratification.
  • Improved risk assessment supports timely and intensified treatment strategies for patients with HF.